Buprenorphine (CODA/Suboxone) and Kidney Safety: Evidence Review
Buprenorphine (in CODA®, Suboxone®, Subutex®, Sublocade®, Brixadi®) has no evidence of direct nephrotoxicity at therapeutic doses for opioid use disorder (OUD).
Renal Pharmacology
- Metabolism: Hepatic (CYP3A4 → norbuprenorphine); glucuronidation.
- Excretion: Feces (70%), urine (30% as glucuronides).
- No dose adjustment for renal impairment (including ESRD on dialysis).
- Not dialyzable (high protein binding, large Vd).
Indirect Renal Considerations
- Hepatitis C/HIV: Common in OUD → renal disease (MPGN, HIVAN).
- Injection Drug Use: Abscesses, endocarditis → septic emboli, glomerulonephritis.
- Rhabdomyolysis: From overdose/coma → AKI (not buprenorphine direct).
- Dehydration: From withdrawal or poor self-care.
Clinical Monitoring
- Baseline Cr, eGFR, UACR if risk factors.
- Periodic monitoring per primary care — not buprenorphine-specific.
- Dose adjustment not required for CKD/ESRD.
Common Side Effects (Non-Renal)
- Constipation, nausea, headache, insomnia, sweating, sedation.
- QTc prolongation (caution with other QT drugs).
- Respiratory depression rare (partial agonist ceiling effect) — but ↑ with benzodiazepines/alcohol.
Buprenorphine is renal-safe. Kidney disease in OUD reflects comorbidities, not the medication. Continue OUD treatment — it reduces overdose mortality by 50–80%.
Kidney Disease - Related Articles
- Kidney Stone Stents: Understanding Their Role in Surgery
- Kidney Disease: Recognizing Early Warning Signs & Symptoms
- Understanding Renal Failure: Causes, Symptoms & Impact
- Kidney Blood Vessels: Arteries, Veins & Capillaries - Renal Function
- Understanding Renal Failure: Causes, Risks & Stages
- Renal Neoplasms: Kidney Tumors – Types, Symptoms, and Treatment
- Understanding and Treating Renal Tubular Acidosis (RTA)
